“…Besides sympatho-inhibitory (I 1 -IR-mediated) and insulin-secretory (pancreatic I 3 -IR-mediated) actions (Bousquet et al, 1984; Chan et al, 1994), putative IR agonists, such as moxonidine (I 1 -selective), BU224 (I 2 -selective) and LSL61122 (mixed I 1 /I 2 -ligand), may have therapeutic potential in various neurological disorders (García-Sevilla et al, 1999; Gupta and Sharma, 2014; Keller and García-Sevilla, 2015a; Li et al, 2012; Piletz, et al, 2000). Notably, I 1 - and I 2 -IR ligands have been shown to exert neuroprotection through reversible blockade of N-methyl-D-aspartate (NMDA) receptors (Han et al, 2013; Jiang et al, 2010; Milhaud et al, 2000; Olmos, DeGregorio-Rocasolano, et al, 1999; Olmos, Ribera, et al, 1996) and activation of presynaptic IRs that can inhibit N-type calcium (Ca 2+ ) currents and repetitive action potential firing (Chung et al, 2010; Kim et al, 2011). Moreover, IR drugs and the I 1 -IR candidate IR antisera-selected (IRAS)/nischarin (Alahari et al, 2000; Piletz, et al, 1999) have been associated with anti-apoptotic and/or cytoprotective functions, as they were shown to reduce the contents of pro-apoptotic proteins and to protect cells from cell death induced by noxious stimuli (Choi et al, 2002; Dontenwill et al, 2003; Garau et al, 2013).…”